Targeted Pulse Quiz: July 28

Encorafenib plus binimetinib demonstrated antitumor activity in patients with treatment-naive BRAF V600E-mutant advanced non–small cell lung cancer.

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and treatment.

In a phase 2 trial, datopotamab deruxtecan plus durvalumab achieved a 50% overall pathologic complete response rate in patients with high-risk HER2-negative breast cancer.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Neoadjuvant endocrine therapy followed by targeted therapy led to excellent survival outcomes in patients with hormone-receptor-positive, HER2-positive early breast cancer.